NO20083520L - Tricykliske N-heteroaryl-karboksamidderivater inneholdende en benzimidazolenhet, fremgangsmate for fremstilling av samme og deres terapeutiske anvendelser - Google Patents
Tricykliske N-heteroaryl-karboksamidderivater inneholdende en benzimidazolenhet, fremgangsmate for fremstilling av samme og deres terapeutiske anvendelserInfo
- Publication number
- NO20083520L NO20083520L NO20083520A NO20083520A NO20083520L NO 20083520 L NO20083520 L NO 20083520L NO 20083520 A NO20083520 A NO 20083520A NO 20083520 A NO20083520 A NO 20083520A NO 20083520 L NO20083520 L NO 20083520L
- Authority
- NO
- Norway
- Prior art keywords
- tricyclic
- preparation
- derivatives containing
- carboxamide derivatives
- same
- Prior art date
Links
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 4
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår tricykliske N-heteroaryl-karboksamidderivater som inneholder en benzimidazolenhet, med generell formel (I) hvori: A representerer, med C-N-bindingen til benzimidazolenheten til hvilken den er bundet, et 4 til 7-leddet monosyklisk heterocykel eller et monosyklisk heteroaryl som inneholder fra 1 til 3 heteroatomer valgt fra O, S eller N, som inkluderer nitrogenatomet til benzimidazolenheten; P representerer et 8-, 9-, 10- eller 11-leddet bicykel eller et bisyklisk heteroaryl, som innebefatter 1 til 6 heteroatomer valgt fra N, O eller S; Ri representerer fra 1 til 4 atomer eller grupper, identiske eller forskjellige; og Y representerer et oksygen- eller svovelatom; R2 representerer et hydrogenatom, et halogenatom, en Ci^alkyl, C3-7cykloalkyl, C3-7cykloalkylCi-3alkylen, Ci^fluoralkyl eller Ci_6alkoksygruppe; R3 representerer fra 1 til 3 atomer eller grupper, identisk eller forskjellige; i base eller syreaddisjonstilstand så vel som i hydrat- eller solvatform. Oppfinnelsen angår også en fremgangsmåte for fremstilling av forbindelsene og deres terapeutiske anvendelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0601007A FR2897061B1 (fr) | 2006-02-03 | 2006-02-03 | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| PCT/FR2007/000183 WO2007088277A1 (fr) | 2006-02-03 | 2007-02-01 | Dérivés de ν-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur préparation et leur application en thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083520L true NO20083520L (no) | 2008-09-11 |
Family
ID=36954977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083520A NO20083520L (no) | 2006-02-03 | 2008-08-13 | Tricykliske N-heteroaryl-karboksamidderivater inneholdende en benzimidazolenhet, fremgangsmate for fremstilling av samme og deres terapeutiske anvendelser |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8143248B2 (no) |
| EP (1) | EP1987010B1 (no) |
| JP (1) | JP5136938B2 (no) |
| KR (1) | KR20080090495A (no) |
| CN (1) | CN101379041B (no) |
| AR (1) | AR059279A1 (no) |
| AT (1) | ATE463484T1 (no) |
| AU (1) | AU2007211399B2 (no) |
| BR (1) | BRPI0710480A2 (no) |
| CA (1) | CA2637333C (no) |
| CY (1) | CY1110168T1 (no) |
| DE (1) | DE602007005779D1 (no) |
| DK (1) | DK1987010T3 (no) |
| DO (1) | DOP2007000022A (no) |
| EA (1) | EA014450B1 (no) |
| ES (1) | ES2344087T3 (no) |
| FR (1) | FR2897061B1 (no) |
| HR (1) | HRP20100327T1 (no) |
| IL (1) | IL192648A (no) |
| JO (1) | JO2602B1 (no) |
| MA (1) | MA30229B1 (no) |
| NO (1) | NO20083520L (no) |
| NZ (1) | NZ569669A (no) |
| PE (1) | PE20071325A1 (no) |
| PL (1) | PL1987010T3 (no) |
| PT (1) | PT1987010E (no) |
| RS (1) | RS51366B (no) |
| SI (1) | SI1987010T1 (no) |
| TW (1) | TWI401256B (no) |
| UY (1) | UY30130A1 (no) |
| WO (1) | WO2007088277A1 (no) |
| ZA (1) | ZA200806139B (no) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2945891B2 (ja) | 1998-02-16 | 1999-09-06 | 大豊建設株式会社 | セグメント継手構造 |
| FR2888848B1 (fr) * | 2005-07-22 | 2007-09-28 | Sanofi Aventis Sa | Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2911605B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique |
| FR2911604B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2919610B1 (fr) * | 2007-08-02 | 2009-10-16 | Sanofi Aventis Sa | Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique |
| FR2926555B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926554B1 (fr) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| FR2926553B1 (fr) * | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| US20110312938A1 (en) * | 2008-06-30 | 2011-12-22 | Ironwood Pharmaceuticals, Inc. | Pyrrolopyridine Carboxylic Acid Derivatives |
| AU2009308687A1 (en) * | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Compounds for the treatment of osteoporosis and cancers |
| JP2012517471A (ja) * | 2009-02-11 | 2012-08-02 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法 |
| EP2475662A2 (en) * | 2009-09-11 | 2012-07-18 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| KR20130069646A (ko) * | 2010-04-27 | 2013-06-26 | 아스텔라스세이야쿠 가부시키가이샤 | 이미다조［１，２－ａ］피리딘 유도체 |
| LT2825541T (lt) | 2012-03-16 | 2016-12-27 | Vitae Pharmaceuticals, Inc. | Kepenų x receptoriaus moduliatoriai |
| CA2865639C (en) * | 2012-03-16 | 2020-12-22 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
| IN2015DN00334A (no) | 2012-06-18 | 2015-06-12 | Dart Neuroscience Cayman Ltd | |
| KR102523430B1 (ko) | 2014-08-04 | 2023-04-19 | 누에볼루션 에이/에스 | 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체 |
| ES2809208T3 (es) * | 2015-06-25 | 2021-03-03 | Promega Corp | Compuestos de tienopirrol y usos de los mismos como inhibidores de luciferasas procedentes de Oplophorus |
| WO2018064557A1 (en) * | 2016-09-30 | 2018-04-05 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
| WO2018125992A1 (en) | 2016-12-28 | 2018-07-05 | Promega Corporation | Functionalized nanoluc inhibitors |
| CA3060416A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN109761974B (zh) * | 2019-01-21 | 2021-05-14 | 河南大学 | 1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚类TRPV1拮抗剂及其应用 |
| PE20230240A1 (es) | 2019-12-20 | 2023-02-07 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CN114276354B (zh) * | 2022-01-07 | 2023-06-02 | 中山大学 | 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用 |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223782B2 (en) * | 2001-11-01 | 2007-05-29 | Icagen, Inc. | Pyrazole-amides and -sulfonamides |
| WO2004007495A1 (ja) * | 2002-07-11 | 2004-01-22 | Takeda Pharmaceutical Company Limited | ピロロピリジン誘導体およびその用途 |
| AU2004209456A1 (en) * | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| GB0322016D0 (en) * | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| MX2007000480A (es) * | 2004-07-15 | 2007-03-29 | Japan Tobacco Inc | Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1. |
-
2006
- 2006-02-03 FR FR0601007A patent/FR2897061B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-30 PE PE2007000106A patent/PE20071325A1/es not_active Application Discontinuation
- 2007-01-31 TW TW096103550A patent/TWI401256B/zh not_active IP Right Cessation
- 2007-02-01 PL PL07730900T patent/PL1987010T3/pl unknown
- 2007-02-01 DK DK07730900.3T patent/DK1987010T3/da active
- 2007-02-01 CN CN2007800042835A patent/CN101379041B/zh not_active Expired - Fee Related
- 2007-02-01 JO JO200729A patent/JO2602B1/en active
- 2007-02-01 RS RSP-2010/0301A patent/RS51366B/sr unknown
- 2007-02-01 AR ARP070100426A patent/AR059279A1/es not_active Application Discontinuation
- 2007-02-01 PT PT07730900T patent/PT1987010E/pt unknown
- 2007-02-01 HR HR20100327T patent/HRP20100327T1/hr unknown
- 2007-02-01 ZA ZA200806139A patent/ZA200806139B/xx unknown
- 2007-02-01 DO DO2007000022A patent/DOP2007000022A/es unknown
- 2007-02-01 CA CA2637333A patent/CA2637333C/fr not_active Expired - Fee Related
- 2007-02-01 BR BRPI0710480-4A patent/BRPI0710480A2/pt not_active IP Right Cessation
- 2007-02-01 NZ NZ569669A patent/NZ569669A/en not_active IP Right Cessation
- 2007-02-01 EA EA200870226A patent/EA014450B1/ru not_active IP Right Cessation
- 2007-02-01 KR KR1020087019041A patent/KR20080090495A/ko not_active Ceased
- 2007-02-01 SI SI200730254T patent/SI1987010T1/sl unknown
- 2007-02-01 JP JP2008552848A patent/JP5136938B2/ja not_active Expired - Fee Related
- 2007-02-01 AU AU2007211399A patent/AU2007211399B2/en not_active Ceased
- 2007-02-01 ES ES07730900T patent/ES2344087T3/es active Active
- 2007-02-01 EP EP07730900A patent/EP1987010B1/fr active Active
- 2007-02-01 AT AT07730900T patent/ATE463484T1/de active
- 2007-02-01 WO PCT/FR2007/000183 patent/WO2007088277A1/fr not_active Ceased
- 2007-02-01 DE DE602007005779T patent/DE602007005779D1/de active Active
- 2007-02-02 UY UY30130A patent/UY30130A1/es not_active Application Discontinuation
-
2008
- 2008-07-06 IL IL192648A patent/IL192648A/en not_active IP Right Cessation
- 2008-08-01 US US12/184,437 patent/US8143248B2/en not_active Expired - Fee Related
- 2008-08-13 NO NO20083520A patent/NO20083520L/no not_active Application Discontinuation
- 2008-08-26 MA MA31193A patent/MA30229B1/fr unknown
-
2010
- 2010-07-01 CY CY20101100609T patent/CY1110168T1/el unknown
-
2012
- 2012-01-24 US US13/357,015 patent/US8288376B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083520L (no) | Tricykliske N-heteroaryl-karboksamidderivater inneholdende en benzimidazolenhet, fremgangsmate for fremstilling av samme og deres terapeutiske anvendelser | |
| CO6400139A2 (es) | Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica | |
| NO20052038L (no) | Ny adeninforbindelse og anvendelse derav | |
| PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| IL164487A0 (en) | 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides | |
| NO20061076L (no) | (Tio)karbamoylsykloheksanderivater som D3/D2 -reseptorantagonister | |
| TW200633991A (en) | Chemical compounds | |
| CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
| NO20073811L (no) | N-(heteroaryl)-1H-indol-2-karboksamidderivater og deres anvendelse som vanilloid TRPV1 reseptorligander | |
| NO20076006L (no) | Acetylenderivater | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
| NO20080871L (no) | N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav | |
| SI2091948T1 (sl) | Novi inhibitorji glutaminil ciklaze | |
| NO20090952L (no) | N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav | |
| GEP20156267B (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| EA201171000A1 (ru) | Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| MY139750A (en) | Cyclohexylamides as dopamine d3, d2 and 5ht1a antagonists | |
| NO20053133L (no) | Kjemiske forbindelser. | |
| NO20053762L (no) | Kondensert furanforbindelse. | |
| NO20070173L (no) | Nye forbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |